[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640331":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":52,"centralContacts":48,"locations":48,"responsibleParty":56,"collaborators":48,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":48,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":48,"enrollmentInfo":67,"targetDuration":48,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":48,"overallStatus":76,"whyStopped":48,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,15,21,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.",[13,14],"Drug: Placebo for MK-7262","Drug: Placebo for enlicitide",{"label":16,"type":17,"description":18,"interventionNames":19},"enlicitide monotherapy","ACTIVE_COMPARATOR","Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment.",[20,13],"Drug: Enlicitide",{"label":22,"type":23,"description":24,"interventionNames":25},"MK-7262 monotherapy","EXPERIMENTAL","Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.",[26,14],"Drug: MK-7262",{"label":28,"type":23,"description":29,"interventionNames":30},"MK-7262 + enlicitide","Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment.",[26,20],[32,39,45,49],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","MK-7262","Oral Coated Tablet",[28,22],[38],"HRS-5346",{"type":33,"name":40,"description":35,"armGroupLabels":41,"otherNames":42},"Enlicitide",[28,16],[43,44],"MK-0616","enlicitide decanoate",{"type":33,"name":46,"description":35,"armGroupLabels":47,"otherNames":48},"Placebo for MK-7262",[9,16],null,{"type":33,"name":50,"description":35,"armGroupLabels":51,"otherNames":48},"Placebo for enlicitide",[22,9],[53],{"name":54,"affiliation":5,"role":55},"Medical Director","STUDY_DIRECTOR",{"type":57,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100640331","phase-2-a-clinical-trial-of-mk-7262-and-enlicitide-in-participants-with-high-lipoproteina-mk-7262-004-100640331",false,"NCT07614984","A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has Lp(a) ≥ 150 nmol\u002FL\n* Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH\n* Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization\n* Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)\n* Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection\n* Has a history of nephrotic syndrome\n* Has severe renal insufficiency\n* Has received certain therapies in the prohibited timeframe as specified in the protocol\n* Has active or chronic hepatobiliary or hepatic disease\n* Has poorly controlled Type 1 or Type 2 diabetes","ALL","18 Years",{"count":68,"type":69},750,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C).\n\nThe goals of this trial are to evaluate:\n\n* if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood\n* if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood\n* the safety and tolerability of taking MK-7262 and enlicitide alone and together",[75],"Lipoprotein(a)","NOT_YET_RECRUITING","2026-05-22",{"date":79,"type":80},"2026-05-29","ACTUAL",{"date":82,"type":69},"2026-07-07",{"date":84,"type":69},"2027-10-12",{"name":5,"class":6}]